Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.

Chin, KL; Collier, TJ; Pitt, B; McMurray, JJ; Swedberg, K; van Veldhuisen, DJ; Pocock, SJ; Vincent, J; Turgonyi, E; Zannad, F; +2 more... Krum, H; EMPHASIS-HF Study Investigators; (2016) Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. European journal of heart failure, 18 (9). pp. 1175-81. ISSN 1388-9842 DOI: https://doi.org/10.1002/ejhf.485

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1002/ejhf.485

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar